CSL Ltd (ASX: CSL) shares are trading at $280.30 on Tuesday, up 0.11% at the time of writing.
The ASX 200 healthcare giant is among many listed companies that have released their corporate calendars for 2025.
Let's review the important dates for CSL investors in the new year.
Key dates for CSL investors in 2025
The CSL share price is more likely to move on days when the company announces big news.
The first important date is less than a month away.
On 11 February, CSL will release its FY25 half-year results and announce its interim dividend.
The ex-dividend date for the interim CSL dividend will be 10 March.
The record date will be 11 March and the dividend will be paid to investors on 9 April.
CSL will announce its FY25 full-year results and final dividend on 19 August.
The ex-dividend date for the final dividend will be 9 September.
The record date will be 10 September and CSL will pay its shareholders on 3 October.
CSL will hold its annual general meeting on 28 October.
What happened to the CSL share price in 2024?
The CSL share price underperformed the benchmark S&P/ASX 200 Index (ASX: XJO) last year.
CSL shares ended 2024 1.77% lower while the ASX 200 gained 7.49% over the 12-month period.
The stock started the year at $286.65 per share and rose to a 52-week high of $313.55 in July.
But it could not sustain this growth.
The decline began after the company released its FY24 results in August.
CSL reported an 11% year-over-year revenue bump (in constant currency) to US$14.8 billion.
Net profit after tax before amortisation (NPATA) in constant currency was 15% higher at US$3.01 billion.
This flowed through to a 12% increase in the annual dividend payment.
Investors were not impressed, and the CSL share price began its painful second-half fall.
The CSL share price was volatile in the final six months of 2024 and eventually ended the year in the red.
Are CSL shares a buy?
As one of Australia's biggest listed companies, CSL receives a lot of broker coverage.
There is a very positive feeling on CSL shares, with many top brokers rating the stock a buy.
Bell Potter has a buy rating on the ASX 200 biotech with a 12-month share price target of $345.
The broker points out that CSL is trading on a 12-month forward price-to-earnings (P/E) ratio of 28x.
This is lower than its 10-year average of 31x.
Macquarie has an outperform rating on CSL and a $334 price target.
Jarden also has an overweight rating on the stock with a price target of $329.62.
Morgans has an add rating on CSL with a $330.75 price target.
UBS has a buy rating and also tips the CSL share price will lift to about $330 by the end of 2025.
